BEAM

Beam Therapeutics Inc

Feb 24 • 04:00PM ET

32.29

+3.96 13.98 %

Healthcare • Biotechnology • USA • NASD

Today, 2:41 PMBeam Therapeutics secures $500M non-dilutive Sixth Street credit facility and reports FDA interactions for BEAM-304 PKU liver program

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK XBI VTI IWM ARKG VB VBK VXF IWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.43	Insider Own	10.28%	Shs Outstand	101.36M	Perf Week	17.46%
Market Cap	3.28B	Forward P/E	-	EPS next Y	-4.37	Insider Trans	-1.31%	Shs Float	91.05M	Perf Month	2.31%
Enterprise Value	2.35B	PEG	-	EPS next Q	-1.00	Inst Own	94.55%	Short Float	21.32%	Perf Quarter	56.75%
Income	-414.64M	P/S	58.83	EPS this Y	-438.74%	Inst Trans	1.94%	Short Ratio	10.91	Perf Half Y	94.05%
Sales	55.70M	P/B	3.39	EPS next Y	-0.09%	ROA	-33.41%	Short Interest	19.41M	Perf YTD	16.49%
Book/sh	9.53	P/C	3.05	EPS next 5Y	-	ROE	-47.19%	52W High	36.44 -11.39%	Perf Year	4.87%
Cash/sh	10.59	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-37.53%	52W Low	13.52 138.74%	Perf 3Y	-17.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	60.38%	Volatility	6.09% 6.54%	Perf 5Y	-66.72%
Dividend TTM	-	EV/Sales	42.25	EPS Y/Y TTM	-157.71%	Oper. Margin	-837.12%	ATR (14)	2.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.02	Sales Y/Y TTM	-84.07%	Profit Margin	-744.41%	RSI (14)	64.11	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	6.02	EPS Q/Q	6.31%	SMA20	15.97%	Beta	2.11	Target Price	49.71
Payout	-	Debt/Eq	0.16	Sales Q/Q	-32.03%	SMA50	12.79%	Rel Volume	2.10	Prev Close	28.33
Employees	483	LT Debt/Eq	0.14	Earnings	Feb 24 BMO	SMA200	41.17%	Avg Volume	1.78M	Price	32.29
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	330.81% 877.88%	Trades		Volume	3,742,561	Change	13.98%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-26	Initiated	Canaccord Genuity	Buy	$74
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130

Show Previous Ratings

Today 02:07PM	What's Going On With Beam Therapeutics Stock? (Benzinga) +13.98%
02:01PM	Beam Therapeutics Inc (BEAM) Q4 2025 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
10:44AM	Beam Therapeutics Q4 Earnings Call Highlights (MarketBeat)
10:44AM	Apellis Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:50AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:01AM	Loading…
07:01AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) (GlobeNewswire)
07:00AM	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street (GlobeNewswire)
Feb-23-26 04:00PM	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program (GlobeNewswire)
Feb-20-26 10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
09:39AM	Walmart downgraded, Etsy upgraded: Wall Street's top analyst calls (The Fly)
Feb-18-26 07:39PM	Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory (Insider Monkey)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
Feb-16-26 12:23PM	Here is Why Beam Therapeutics (BEAM) Appears so Attractive (Insider Monkey)
05:42AM	Cathie Wood Buys COIN After 16% Jump (GuruFocus.com)
Feb-15-26 11:33PM	Cathie Wood buys $46 million of tumbling tech stock (TheStreet)
08:41AM	Loading…
08:41AM	H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval (Insider Monkey)
Jan-29-26 07:17AM	Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) (Insider Monkey)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 04:15PM	Beam Soars 22% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily) +22.29%
03:37PM	Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference (MarketBeat)
01:39PM	Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? (Benzinga)
12:54PM	Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition (GlobeNewswire)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.59%
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:46PM	Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene (Insider Monkey)
07:33AM	Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? (Insider Monkey)
12:51PM	Loading…
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-22-25 06:50AM	BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy (Insider Monkey) +5.08%
Dec-18-25 04:01PM	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-06-25 08:00AM	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks) +8.12%
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.82%
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga)
07:00AM	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-25 08:16PM	Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
Nov-04-25 03:37PM	Cathie Wood unloads $7.69 million in top AI stock (TheStreet) -6.23%
03:37PM	Cathie Wood sells another $7.69 million in leading AI stock (TheStreet)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
09:00AM	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks) +5.08%
01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
Oct-30-25 12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks) -6.28%
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:55AM	Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-25 09:55AM	Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +17.86%
09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GIUSEPPE CIARAMELLA	Officer	Feb 24 '26	Proposed Sale	32.00	35,000	1,120,042		Feb 24 04:15 PM
Evans John M.	CEO	Jan 29 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 29 '26	Sale	29.38	25,000	734,582	986,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Sale	28.36	25,000	708,946	986,667	Feb 02 04:05 PM
JOHN M EVANS	Officer	Jan 30 '26	Proposed Sale	28.36	25,000	708,948		Jan 30 04:04 PM
JOHN M EVANS	Officer	Jan 29 '26	Proposed Sale	29.38	25,000	734,582		Jan 29 04:01 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 22 '26	Sale	35.00	6,198	216,933	34,813	Jan 26 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 22 '26	Sale	34.00	1,371	46,614	95,667	Jan 26 04:05 PM
CHRISTINE BELLON	Officer	Jan 22 '26	Proposed Sale	34.00	1,371	46,614		Jan 22 04:03 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 20 '26	Sale	30.12	3,034	91,384	41,011	Jan 21 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 15 '26	Sale	34.61	18,629	644,832	97,038	Jan 20 04:05 PM
CHRISTINE BELLON	Officer	Jan 15 '26	Proposed Sale	34.61	18,629	644,831		Jan 15 06:00 PM
Emany Sravan Kumar	Chief Financial Officer	Dec 31 '25	Sale	27.10	6,294	170,567	73,706	Jan 05 04:16 PM
Bellon Christine	Chief Legal Officer	Dec 31 '25	Sale	27.10	1,254	33,983	115,667	Jan 05 04:12 PM
FMR LLC	See Remark 1	Oct 27 '25	Sale	26.68	459	12,246	14	Oct 29 01:13 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '25	Sale	24.53	467	11,456	44,045	Oct 03 04:15 PM
Bellon Christine	Chief Legal Officer	Oct 01 '25	Sale	24.53	373	9,150	116,921	Oct 03 04:10 PM
Evans John M.	CEO	Oct 01 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Sale	24.63	25,000	615,668	986,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 01 '25	Sale	24.51	25,000	612,655	986,667	Oct 03 04:05 PM
JOHN M EVANS	Officer	Oct 02 '25	Proposed Sale	24.63	25,000	615,668		Oct 02 04:23 PM
JOHN M EVANS	Officer	Oct 01 '25	Proposed Sale	24.51	25,000	612,655		Oct 01 04:12 PM
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience